1. RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data.
- Author
-
Kafatos G, Niepel D, Lowe K, Jenkins-Anderson S, Westhead H, Garawin T, Traugottová Z, Bilalis A, Molnar E, Timar J, Toth E, Gouvas N, Papaxoinis G, Murray S, Mokhtar N, Vosmikova H, Fabian P, Skalova A, Wójcik P, Tysarowski A, Barugel M, van Krieken JH, and Trojan J
- Subjects
- Colorectal Neoplasms epidemiology, Colorectal Neoplasms mortality, Exons, Humans, Mutation, Prevalence, Proto-Oncogene Proteins B-raf genetics, Survival Rate, Biomarkers, Tumor genetics, Colorectal Neoplasms pathology, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources., Materials & Methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses., Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources., Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.
- Published
- 2017
- Full Text
- View/download PDF